Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2,035 DKK | +0.25% | -1.07% | -5.52% |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.52% | 18.79B | |
+2.49% | 96.73B | |
-0.38% | 21.31B | |
-16.61% | 21.21B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B | |
+12.82% | 8.12B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S : , Bolt Biotherapeutics Partner to Develop Candidate Drugs Against Cancer